ORIC

ORIC Pharmaceuticals, Inc.

NasdaqGSUSDEQUITY DELAYED

14.13

▲ 0.25 (1.80%)

MARKET · —

Price

Open

14.21

Prev close

13.88

Day high

14.34

Day low

13.81

Volume

950.57K

Market cap

—

P/E (TTM)

—

52W range

7.23 – 14.93

Trailing performance

Price return · vs SPY

Returnvs SPY

+2.38% +3.7%

+30.39% +26.7%

+67.85% +64.8%

+27.81% +16.7%

YTD

+73.59% +61.3%

+49.32% +29.3%

+53.68% -20.5%

— —

Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.

Fundamentals

TTM · reported

Market cap—

Enterprise value—

Revenue (TTM)—

Gross profit—

EBITDA—

Net income—

EPS (TTM)—

Free cash flow—

Total cash—

Total debt—

Book value / share—

Shares outstanding—

Float—

Short % of float—

Dividend yield—

Beta (5Y)—

Valuation & profitability ratios

Account required

Trailing P/E—

Forward P/E—

PEG ratio—

Price / sales—

Price / book—

EV / revenue—

EV / EBITDA—

Gross margin—

Operating margin—

Profit margin—

Return on equity—

Return on assets—

Debt / equity—

Current ratio—

Free account required

Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.

Create free account Sign in

Analyst targets & ownership

Account required

Mean target—

High target—

Low target—

Implied upside—

Analyst count—

Consensus—

Strong buy / Buy— / —

Hold—

Sell / Strong sell— / —

Held by insiders—

Held by institutions—

Institutions holding—

Free account required

Price targets, consensus spread, insider and institutional ownership.

Create free account Sign in

Moving averages & technicals

Computed from 2Y daily closes

SMA 10

13.87

+1.86% from price

SMA 20

13.00

+9.20% from price

SMA 50

11.26

+26.14% from price

SMA 100

10.21

+38.46% from price

SMA 200

10.62

+33.76% from price

EMA 12

13.62

+3.72% from price

EMA 26

12.75

+10.80% from price

EMA 50

11.77

+20.02% from price

RSI (14)

63.3

Neutral

MACD (12,26,9)

0.87

Hist 0.02

ATR (14)

0.87

6.16% of price

Realised vol 30D

89.6%

Annualised

Bollinger upper

15.27

20, 2σ

Bollinger lower

10.74

20, 2σ

50 / 200 cross

Golden

11.26 vs 10.62

Trend bias

Above 200

+33.76%

Risk profile

Daily returns · 1Y window

Beta vs SPY

1.48

More volatile than market

Correlation to SPY

0.22

Largely independent

Realised vol 30D

89.6%

Annualised

Market vol 1Y

12.9%

SPY, annualised

Max drawdown 1Y

-48.1%

Peak to trough

Max drawdown 5Y

-90.3%

Peak to trough

ATR 14

0.87

6.16% of price

Beta (reported)

—

5Y monthly, from filing

Options chain

Account required

ExpirySpot 14.13

Calls

Strike	Last	Bid	Ask	Vol	OI	IV
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%

Puts

Strike	Last	Bid	Ask	Vol	OI	IV
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%

Free account required

Every listed expiry, both sides of the book, with volume, open interest and implied volatility.

Create free account Sign in

Headlines

ORIC · links out to the publisher

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire · 15d ago Is ORIC Pharmaceuticals' (ORIC) Equity-Funded ESOP Masking or Clarifying Its Widening Net Losses? Simply Wall St. · 15d ago ORIC® Pharmaceuticals Reports Second Quarter 2026 Financial Results and Operational Updates GlobeNewswire · 19d ago ORIC® Pharmaceuticals Announces Three Presentations at the European Society for Medical Oncology (ESMO) Congress 2026 GlobeNewswire · 33d ago ORIC Pharmaceuticals Starts Phase 3 Trial of Rinzimetostat in Metastatic Prostate Cancer MT Newswires · 39d ago ORIC® Pharmaceuticals Announces Initiation of Himalayas-1 Phase 3 Trial in mCRPC Evaluating Rinzimetostat in Combination with NUBEQA® (Darolutamide), Supported by Clinical Collaboration with Bayer GlobeNewswire · 39d ago ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences GlobeNewswire · 87d ago

PRIVATE STRATEGY · BY QUALIFICATION

The same data. A different seat.

The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.